Coeptis Therapeutics Inc (NASDAQ:COEP) — Market Cap & Net Worth
Market Cap & Net Worth: Coeptis Therapeutics Inc (COEP)
Coeptis Therapeutics Inc (NASDAQ:COEP) has a market capitalization of $68.21 Million ($68.21 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20664 globally and #4446 in its home market, demonstrating a 19.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Coeptis Therapeutics Inc's stock price $16.40 by its total outstanding shares 4820317 (4.82 Million). Analyse Coeptis Therapeutics Inc operating cash flow efficiency to see how efficiently the company converts income to cash.
Coeptis Therapeutics Inc Market Cap History: 2020 to 2026
Coeptis Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows growth from $49.12 Million to $79.05 Million (9.89% CAGR).
Index Memberships
Coeptis Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #595 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2002 of 3165 |
Weight: Coeptis Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Coeptis Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Coeptis Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
642.71x
Coeptis Therapeutics Inc's market cap is 642.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $49.12 Million | $30.76K | -$9.16 Million | 1596.80x | N/A |
| 2021 | $48.20 Million | $75.00K | -$13.45 Million | 642.71x | N/A |
Competitor Companies of COEP by Market Capitalization
Companies near Coeptis Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Coeptis Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Coeptis Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Coeptis Therapeutics Inc's market cap moved from $49.12 Million to $ 79.05 Million, with a yearly change of 9.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $79.05 Million | +15.09% |
| 2025 | $68.69 Million | +159.09% |
| 2024 | $26.51 Million | +601.53% |
| 2023 | $3.78 Million | -48.79% |
| 2022 | $7.38 Million | -84.69% |
| 2021 | $48.20 Million | -1.86% |
| 2020 | $49.12 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Coeptis Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $68.21 Million USD |
| MoneyControl | $68.21 Million USD |
| MarketWatch | $68.21 Million USD |
| marketcap.company | $68.21 Million USD |
| Reuters | $68.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Coeptis Therapeutics Inc
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy tec… Read more